All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

August 18th 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies for Patients

August 18th 2023

Researchers at City of Hope were awarded $32.3 million from the CIRM to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia.

Belzutifan Improves PFS in Pretreated Advanced RCC

August 18th 2023

Treatment with belzutifan demonstrated a statistically significant and clinically meaningful improvement in progression-free survivalcompared with everolimus in patients with advanced renal cell carcinoma that has progressed on prior PD-1/PD-L1 and VEGF inhibitors, in sequence or in combination.

European Commission Approves Reduced Dosing of Teclistamab in Relapsed/Refractory Myeloma

August 18th 2023

The European Commission has approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma who have achieved a complete response or better for a minimum of 6 months.

Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features

August 18th 2023

Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.

Ociperlimab Plus Tislelizumab/Chemo Has Antitumor Activity in Stage IV Gastric/GEJ Cancers

August 18th 2023

The combination of ociperlimab, tislelizumab, and chemotherapy elicited responses in patients with stage IV gastric or gastroesophageal junction cancer, irrespective of PD-L1 expression.

Zanubrutinib Sustains Response, Safety Benefits Vs Ibrutinib in Waldenström Macroglobulinemia

August 17th 2023

Zanubrutinib demonstrated long-term efficacy with superior tolerability compared with ibrutinib for the treatment of patients with symptomatic Waldenström macroglobulinemia regardless of CXCR4 or MYD88 mutational status.

Selective Use of Neoadjuvant Chemoradiation Is a Viable Approach in Locally Advanced Rectal Cancer

August 17th 2023

Deb Schrag, MD, MPH, discusses the rationale for exploring the use of selective preoperative chemoradiation in patients with locally advanced rectal cancer, the safety and efficacy findings from the PROSPECT trial, and the importance of reviewing patient-reported outcomes during clinical trials.

Frontline Quizartinib Plus Chemotherapy Shows Curative Potential in FLT3-ITD Wild-Type AML

August 17th 2023

The addition of quizartinib to standard induction and consolidation chemotherapy with idarubicin plus cytarabine followed by maintenance therapy led to an improvement in event-free survival compared with placebo plus chemotherapy in patients with FLT3-ITD wild-type acute myeloid leukemia.

Tazemetostat Plus Lenalidomide and Rituximab Under Investigation in R/R Follicular Lymphoma

August 17th 2023

Jennifer Effie Amengual, MD, discusses unmet needs in FL that SYMPHONY-1 aims to address; the potential benefits of tazemetostat plus lenalidomide and rituximab in patients who are refractory to rituximab or who relapse within 24 months of their initial therapy; and where this regimen may fit into the relapsed/refractory FL treatment paradigm alongside investigative CAR T-cell therapies.

Jayan Nair, MD Joins Clinical Team at FCS Sarasota Downtown Location

August 17th 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist Jayan Nair, MD has joined the the Sarasota Downtown clinical team.

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17th 2023

The European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refractory follicular lymphoma or relapsed/refractory diffuse large B-cell lymphoma who have progressed after at least 2 prior systemic therapies.

FDA Grants Orphan Drug Designation to NXP800 for Cholangiocarcinoma

August 17th 2023

The FDA has granted an orphan drug designation to NXP800 for the treatment of patients with cholangiocarcinoma.

On-Pathway Regimens Are Associated With Significant Cost Savings for Treatment of Solid Tumors

August 17th 2023

Findings from a cross-institutional study suggest that on-pathway regimens led to significant cost savings for patients with cancer, despite the rate of hospitalizations and immune-related adverse events being similar between on-pathway and off-pathway regimens.

Pembrolizumab Elicits Long-Term Survival Benefit in Advanced Melanoma

August 17th 2023

Pembrolizumab demonstrated long-term survival benefit compared with ipilimumab in patients with unresectable stage III/IV melanoma who received up to 1 prior systemic therapy.

Randall Discusses the Importance of Identifying and Managing Chondroblastoma in Clinical Practice

August 16th 2023

R. Lor Randall, MD, FACS, explains the difference between noncancerous chondroblastoma and other bone neoplasms, details the typical diagnosis and treatment of this rare condition, and emphasizes the importance of pediatric and medical oncologists being able to identify it in clinic.

FDA Grants Breakthrough Device Designation to HLA-LOH Companion Diagnostic Test

August 16th 2023

The FDA has granted a breakthrough device designation to HLA-LOH as a companion diagnostic test, according to an announcement from Tempus.

NK T-Cell Agonist Under Investigation in Combination With Pembrolizumab in Melanoma and NSCLC

August 16th 2023

The natural killer T-cell agonist IMM60 may overcome resistance to PD-1 inhibitors when combined with immunotherapy in patients with melanoma and non–small cell lung cancer.

Repotrectinib Sustains ORR, Safety in Locally Advanced or Metastatic ROS1+ NSCLC

August 16th 2023

Treatment with repotrectinib continued to produce high and durable responses with a manageable safety profile in patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer who were naïve to a TKI or previously treated with 1 TKI and no chemotherapy.

Tucatinib/Letrozole/Palbociclib Combination Demonstrates Meaningful Efficacy in HR+/HER2+ mBC

August 16th 2023

Treatment with the all-oral triplet of tucatinib, letrozole, and palbociclib yielded clinically meaningful efficacy results and had an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.